Recombinant glycoprotein E produced in mammalian cells in large-scale as an antigen for varicella-zoster-virus serology

Journal of Virological Methods

Volumn 175, Issue 1, 2011, Pages 53-59

  Thomsson, Elisabeth ^a   Persson, Linn ^b   Grahn, Anna ^b   Snäll, Johanna ^b   Ekblad, Maria ^b   Brunhage, Eva ^b   Svensson, Frida ^b   Jern, Christina ^a   Hansson, Gunnar C ^b   Bäckström, Malin ^a,b   Bergström, Tomas ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Chinese Hamster Ovary cells; Glycoprotein E; Immunoglobulin G; Mammalian protein expression; Serological antigen; Varicella zoster virus

Indexed keywords

GLYCOPROTEIN E; IMMUNOGLOBULIN G ANTIBODY; MEMBRANE ANTIGEN; RECOMBINANT ANTIGEN; VIRUS ANTIGEN;

ANIMAL CELL; ANTIGEN ANTIBODY REACTION; ANTIGEN SPECIFICITY; ARTICLE; BLOOD DONOR; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN SECRETION; PROTEIN STABILITY; SENSITIVITY AND SPECIFICITY; SEROLOGY; SEROPREVALENCE; STROKE PATIENT; VARICELLA ZOSTER VIRUS;

ADULT; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BLOTTING, WESTERN; CELL LINE; CRICETINAE; CRICETULUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOGLOBULIN G; MALE; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS; VIRAL ENVELOPE PROTEINS;

CRICETULUS GRISEUS; HUMAN HERPESVIRUS 3; MAMMALIA;

EID: 79957970870     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2011.04.014     Document Type: Article

References (27)

1. Andersen D.C., Goochee C.F. The effect of cell-culture conditions on the oligosaccharide structures of secreted glycoproteins. Curr. Opin. Biotechnol. 1994, 5:546-549.
2. Arvin A.M. Varicella-zoster virus: molecular virology and virus-host interactions. Curr. Opin. Microbiol. 2001, 4:442-449.
3. Bäckström M., Thomsson K.A., Karlsson H., Hansson G.C. Sensitive liquid chromatography-electrospray mass spectrometry allows for the analysis of the O-glycosylation of immunoprecipitated proteins from cells or tissues: application to MUC1 glycosylation in cancer. J. Proteome Res. 2009, 8:538-545.
4. Bergström T. Polymerase chain reaction for diagnosis of varicella zoster virus central nervous system infections without skin manifestations. Scand. J. Infect. Dis. Suppl. 1996, 100:41-45.
5. Breuer J., Schmid D.S., Gershon A.A. Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough disease in vaccinees and to screen for susceptibility to varicella. J. Infect. Dis. 2008, 197(Suppl 2):S147-151.
6. Butler M. Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals. Appl. Microbiol. Biotechnol. 2005, 68:283-291.
7. Forghani B., Schmidt N.J., Dennis J. Antibody assays for varicella-zoster virus: comparison of enzyme immunoassay with neutralization, immune adherence hemagglutination, and complement fixation. J. Clin. Microbiol. 1978, 8:545-552.
8. Fowler W.J., Garcia-Valcarcel M., Hill-Perkins M.S., Murphy G., Harper D.R., Jeffries D.J., Burns N.R., Adams S.E., Kingsman A.J., Layton G.T. Identification of immunodominant regions and linear B cell epitopes of the gE envelope protein of varicella-zoster virus. Virology 1995, 214:531-540.
9. Furuta Y., Ohtani F., Aizawa H., Fukuda S., Kawabata H., Bergström T. Varicella-zoster virus reactivation is an important cause of acute peripheral facial paralysis in children. Pediatr. Infect. Dis. J. 2005, 24:97-101.
10. Hansen H.A., Emborg C. Influence of ammonium on growth, metabolism, and productivity of a continuous suspension Chinese hamster ovary cell culture. Biotechnol. Prog. 1994, 10:121-124.
11. Haumont M., Jacquet A., Massaer M., Deleersnyder V., Mazzu P., Bollen A., Jacobs P. Purification, characterization and immunogenicity of recombinant varicella-zoster virus glycoprotein gE secreted by Chinese hamster ovary cells. Virus Res. 1996, 40:199-204.
12. Jacquet A., Haumont M., Massaer M., Garcia L., Mazzu P., Daminet V., Gregoire D., Jacobs P., Bollen A. Immunogenicity of a recombinant varicella-zoster virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and zoster reactivation. Vaccine 2002, 20:1593-1602.
13. Jenkins N., Parekh R.B., James D.C. Getting the glycosylation right: implications for the biotechnology industry. Nat. Biotechnol. 1996, 14:975-981.
14. Koskiniemi M., Piiparinen H., Rantalaiho T., Eranko P., Farkkila M., Raiha K., Salonen E.M., Ukkonen P., Vaheri A. Acute central nervous system complications in varicella zoster virus infections. J. Clin. Virol. 2002, 25:293-301.
15. Kuhn J.E., Klaffke K., Munk K., Braun R.W. HSV-1 gB and VZV gp-II crossreactive antibodies in human sera. Arch. Virol. 1990, 112:203-213.
16. Kunkel J.P., Jan D.C., Jamieson J.C., Butler M. Dissolved oxygen concentration in serum-free continuous culture affects N-linked glycosylation of a monoclonal antibody. J. Biotechnol. 1998, 62:55-71.
17. Link T., Bäckström M., Graham R., Essers R., Zorner K., Gätgens J., Burchell J., Taylor-Papadimitriou J., Hansson G.C., Noll T. Bioprocess development for the production of a recombinant MUC1 fusion protein expressed by CHO-K1 cells in protein-free medium. J. Biotechnol. 2004, 110:51-62.
18. Litwin V., Jackson W., Grose C. Receptor properties of two varicella-zoster virus glycoproteins, gpI and gpIV, homologous to herpes simplex virus gE and gI. J. Virol. 1992, 66:3643-3651.
19. Mogensen T.H., Larsen C.S. Aseptic meningitis caused by reactivation of varicella-zoster virus in two immunocompetent patients. Scand. J. Infect. Dis. 2006, 38:815-818.
20. Nyberg G.B., Balcarcel R.R., Follstad B.D., Stephanopoulos G., Wang D.I. Metabolic effects on recombinant interferon-gamma glycosylation in continuous culture of Chinese hamster ovary cells. Biotechnol. Bioeng. 1999, 62:336-347.
21. Oladepo D.K., Klapper P.E., Percival D., Vallely P.J. Serological diagnosis of varicella-zoster virus in sera with antibody-capture enzyme-linked immunosorbent assay of IgM. J. Virol. Methods 2000, 84:169-173.
22. Persson A., Bergström T., Lindh M., Namvar L., Studahl M. Varicella-zoster virus CNS disease-viral load, clinical manifestations and sequels. J. Clin. Virol. 2009, 46:249-253.
23. Raska M., Takahashi K., Czernekova L., Zachova K., Hall S., Moldoveanu Z., Elliott M.C., Wilson L., Brown R., Jancova D., Barnes S., Vrbkova J., Tomana M., Smith P.D., Mestecky J., Renfrow M.B., Novak J. Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. J. Biol. Chem. 2010, 285:20860-20869.
24. Steiner I., Budka H., Chaudhuri A., Koskiniemi M., Sainio K., Salonen O., Kennedy P.G. Viral meningoencephalitis: a review of diagnostic methods and guidelines for management. Eur. J. Neurol. 2010, 17. 999-e957.
25. Vafai A. Antibody-binding sites on truncated forms of varicella-zoster virus gpI(gE) glycoprotein. Vaccine 1994, 12:1265-1269.
26. Vandvik B., Skoldenberg B., Forsgren M., Stiernstedt G., Jeansson S., Norrby E. Long-term persistence of intrathecal virus-specific antibody responses after herpes simplex virus encephalitis. J. Neurol. 1985, 231:307-312.
27. Wurm F.M. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 2004, 22:1393-1398.